News | September 28, 2021
Bal Pharma ramps up API capacity of Gliclazide
In terms of volume, the company commands a market share 25 per cent globally for Gliclazide, as per the IQVIA report
In terms of volume, the company commands a market share 25 per cent globally for Gliclazide, as per the IQVIA report
It is a recombinant nanoparticle protein-based vaccine
Cephalosporin is a bactericidal, broad-spectrum, and P-lactam antibiotic originally derived from the fungus Acremonium, which is used to treat bacterial infections such as pneumonia, skin infections, ear infection, strep throat, staph infections, tonsillitis, bronchitis among others
The event will include an exhibition and sector-wise sessions for two days with participation by officials from the Ministry of Commerce, export promotion councils and members of the industry
A long waiting period for critical equipment and a 50% hike in the cost of APIs imported from China are among the immediate challenges
The DGTR has recommended US $ 3.2 per kg and US $ 3.55 per kg duty on imports
The revenues and profits derived from the new subsidiary will be consolidated in the parent company
_256_384.jpeg)
The company aims to continue its expansion via organic and inorganic routes to increase production capacity and product portfolio
In H1FY21, it attracted PE deals worth US $ 1.6 billion compared to US $ 3 billion in CY2020
India’s dependency on China for pharma intermediates can change if there is a proper coordination between educational institutes, research institutes and pharma manufacturers
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
